 |
市場調査レポート
商品コード
1140626
重症下肢虚血治療市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2022年～2031年）Critical Limb Ischemia Treatment Market (Treatment: Medications, and Devices: Embolic Protection Devices and Peripheral Dilatation System) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031 |
||||||
● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。 詳細はお問い合わせください。
価格
| 重症下肢虚血治療市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2022年～2031年） |
|
出版日: 2022年08月12日
発行: Transparency Market Research
ページ情報: 英文 211 Pages
納期: 2～10営業日
|
- 全表示
- 概要
- 図表
- 目次
概要
当レポートでは、世界の重症下肢虚血治療市場について調査し、市場の概要とともに、2022年～2031年の予測、治療別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。
目次
第1章 序文
第2章 前提と調査手法
第3章 エグゼクティブサマリー
第4章 市場概要
- 製品の概要
- 市場力学
- 促進要因と促進要因のスナップショット分析
- 促進要因
- 抑制要因
- 機会
- 世界の重症下肢虚血治療市場の収益予測（100万米ドル）、2017年～2027年
- 世界の重症下肢虚血治療市場の見通し
第5章 市場の見通し
- パイプライン分析
- 主要な業界イベント
- デバイスの規制シナリオ
- 世界/地域における重症虚血肢の有病率
- 参画する主な研究機関
- 技術の進歩
第6章 世界の重症下肢虚血治療市場分析、治療別
- 主な調査結果
- イントロダクション
- 世界の重症下肢虚血治療市場価値シェアと魅力分析、治療別
- 世界の重症下肢虚血治療市場予測、治療別
- 装置
- 薬剤
- 世界の重症下肢虚血治療市場分析、治療別
第7章 世界の重症下肢虚血治療市場分析、地域別
- 国別の世界の重症下肢虚血治療市場シナリオ
- 世界の重症下肢虚血治療市場価値シェアと魅力分析、地域別
- 世界の重症下肢虚血治療市場予測、地域別
- 北米
- 欧州
- アジア太平洋
- ラテンアメリカ
- 中東・アフリカ
第8章 北米の重症下肢虚血治療市場分析
第9章 欧州の重症下肢虚血治療市場分析
第10章 アジア太平洋の重症下肢虚血治療市場分析
第11章 ラテンアメリカの重症下肢虚血治療市場分析
第12章 中東・アフリカの重症下肢虚血治療市場分析
第13章 競合情勢
- 競合マトリクス
- 企業プロファイル
- Medtronic plc
- Boston Scientific Corporation
- Cesca Therapeutics, Inc.
- Abbott Laboratories
- Pluristem Therapeutics, Inc.
- Rexgenero Ltd.
- LimFlow SA
- Micro Medical Solutions
- Cardiovascular Systems, Inc.
図表
List of Tables
- Table 01: Pipeline Analysis
- Table 02: Global Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2022-2031
- Table 03: Global Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2022-2031
- Table 04: Global Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2022-2031
- Table 05: Global Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2022-2031
- Table 06: Global Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Region, 2022-2031
- Table 07: North America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Country, 2022-2031
- Table 08: North America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2022-2031
- Table 09: North America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Devices, 2022-2031
- Table 10: North America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Peripheral Dilatation System, 2022-2031
- Table 11: North America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Medication, 2022-2031
- Table 12: Europe Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2022-2031
- Table 13: Europe Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2022-2031
- Table 14: Europe Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Devices, 2022-2031
- Table 15: Europe Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Peripheral Dilatation System, 2022-2031
- Table 16: Europe Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Medication, 2022-2031
- Table 17: Asia Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2022-2031
- Table 18: Asia Pacific Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2022-2031
- Table 19: Asia Pacific Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Devices, 2022-2031
- Table 20: Asia Pacific Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Peripheral Dilatation System, 2022-2031
- Table 21: Asia Pacific Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Medication, 2022-2031
- Table 22: Latin America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2022-2031
- Table 23: Latin America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2022-2031
- Table 24: Latin America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Devices, 2022-2031
- Table 25: Latin America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Peripheral Dilatation System, 2022-2031
- Table 26: Latin America Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Medication, 2022-2031
- Table 27: Middle East & Africa Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2022-2031
- Table 28: Middle East & Africa Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2022-2031
- Table 29: Middle East & Africa Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Devices, 2022-2031
- Table 30: Middle East & Africa Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Peripheral Dilatation System,
- Table 31: Middle East & Africa Critical Limb Ischemia Treatment Market Size (US$ Mn) Forecast, by Medication, 2022-2031
- Table 32: Medtronic plc, Business Overview
- Table 33: Boston Scientific Corporation Product Offerings
- Table 34: Cesca Therapeutics Inc., Products & Services Offered
- Table 35: Abbott Laboratories, Business Overview
- Table 36: Pluristem Therapeutics Inc., Products & Services Offered
- Table 37: Rexgenero Ltd, Products & Services Offered
- Table 38: LimFlow SA, Products & Services Offered
- Table 39: Micro Medical Solutions, Products & Services Offered
- Table 40: Cardiovascular Systems, Inc., Products & Services Offered
List of Figures
- Figure 01: Global Critical Limb Ischemia Treatment Market Size (US$ Mn) and Distribution, by Region, 2021 and 2031
- Figure 02: Global Critical Limb Ischemia Treatment Market Revenue Projection (US$ Mn), 2022-2031
- Figure 03: Global Critical Limb Ischemia Treatment Market Value Share, by Treatment, 2021
- Figure 04: Global Critical Limb Ischemia Treatment Market Value Share, by Region, 2021
- Figure 05: U.S. FDA Medical Devices Approval Criteria
- Figure 06: Classification of Medical Devices
- Figure 07: European Approval for Medical Devices - Regulatory Pathway (Class IIb Devices only)
- Figure 08: Regulatory Approval Process - U.S.
- Figure 09: Regulatory Approval Process - Europe
- Figure 10: Regulatory Approval Process - Japan
- Figure 11: Prevalence of Critical Limb Ischemia Globally/Region
- Figure 12: Global Critical Limb Ischemia Treatment Market Value Share Analysis, by Treatment, 2021 and 2031
- Figure 13: Global Critical Limb Ischemia Treatment Market Attractiveness Analysis, by Treatment, 2022-2031
- Figure 14: Global Critical Limb Ischemia Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Devices, 2022-2031
- Figure 15: Global Critical Limb Ischemia Treatment Market Value (US$ Mn) and Y-o-Y Growth, by Medication, 2022-2031
- Figure 16: Global Critical Limb Ischemia Treatment Market Value Share, by Region, 2021 and 2031
- Figure 17: Global Critical Limb Ischemia Treatment Market Attractiveness Analysis, by Region, 2022-2031
- Figure 18: North America Critical Limb Ischemia Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2031
- Figure 19: North America Critical Limb Ischemia Treatment Market Value Share Analysis, by Country, 2021 and 2031
- Figure 20: North America Critical Limb Ischemia Treatment Market Attractiveness Analysis, by Country, 2022-2031
- Figure 21: North America Critical Limb Ischemia Treatment Market Value Share Analysis, by Treatment, 2021 and 2031
- Figure 22: North America Critical Limb Ischemia Treatment Market Attractiveness Analysis, by Treatment, 2022-2031
- Figure 23: Europe Critical Limb Ischemia Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2031
- Figure 24: Europe Critical Limb Ischemia Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
- Figure 25: Europe Critical Limb Ischemia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
- Figure 26: Europe Critical Limb Ischemia Treatment Market Value Share Analysis, by Treatment, 2021 and 2031
- Figure 27: Europe Critical Limb Ischemia Treatment Market Attractiveness Analysis, by Treatment, 2022-2031
- Figure 28: Asia Pacific Critical Limb Ischemia Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2031
- Figure 29: Asia Pacific Critical Limb Ischemia Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
- Figure 30: Asia Pacific Critical Limb Ischemia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
- Figure 31: Asia Pacific Critical Limb Ischemia Treatment Market Value Share Analysis, by Treatment, 2021 and 2031
- Figure 32: Asia Pacific Critical Limb Ischemia Treatment Market Attractiveness Analysis, by Treatment, 2022-2031
- Figure 33: Latin America Critical Limb Ischemia Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2031
- Figure 34: Latin America Critical Limb Ischemia Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
- Figure 35: Latin America Critical Limb Ischemia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
- Figure 36: Latin America Critical Limb Ischemia Treatment Market Value Share Analysis, by Treatment, 2021 and 2031
- Figure 37: Latin America Critical Limb Ischemia Treatment Market Attractiveness Analysis, by Treatment, 2022-2031
- Figure 38: Middle East & Africa Critical Limb Ischemia Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2031
- Figure 39: Middle East & Africa Critical Limb Ischemia Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
- Figure 40: Middle East & Africa Critical Limb Ischemia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
- Figure 41: Middle East & Africa Critical Limb Ischemia Treatment Market Value Share Analysis, by Treatment, 2021 and 2031
- Figure 42: Middle East & Africa Critical Limb Ischemia Treatment Market Attractiveness Analysis, by Treatment, 2022-2031
- Figure 43: Medtronic plc, Revenue (US$ Mn) and Y-o-Y Growth (%), 2018-2021
- Figure 44: Medtronic plc, Breakdown of Net Sales (%), by Geography, 2021
- Figure 45: Medtronic plc, Breakdown of Net Sales (%), by Business Segment, 2021
- Figure 46: Medtronic plc, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018-2021
- Figure 47: Boston Scientific Corporation, Revenue (US$ Bn) and Y-o-Y Growth (%), 2018-2021
- Figure 48: Boston Scientific Corporation, Breakdown of Net Sales, by Region, 2021
- Figure 49: Boston Scientific Corporation, Breakdown of Net Sales, by Business Segment, 2021
- Figure 50: Cesca Therapeutics Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2018-2021
- Figure 51: Cesca Therapeutics Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018-2021
- Figure 52: Cesca Therapeutics Inc. Breakdown of Net Sales, by Region, 2021
- Figure 53: Cesca Therapeutics Inc. Sales & Marketing Expenses (US$ Mn) and Y-o-Y Growth (%), 2018-2021
- Figure 54: Abbott Laboratories, Revenue (US$ Mn) and Y-o-Y Growth (%), 2018-2021
- Figure 55: Abbott Laboratories, R&D Intensity and Sales & Marketing Intensity (US$ Mn), 2018-2021
- Figure 56: Abbott Laboratories, Breakdown of Net Sales, by Countries, 2021
- Figure 57: Abbott Laboratories, Breakdown of Net Sales, by Business Segment, 2021
- Figure 58: Cardiovascular Systems, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018-2021
- Figure 59: Cardiovascular Systems, Inc. R&D Intensity and Sales & Marketing Intensity (US$ Mn), 2018-2021
目次
Product Code: TMRGL2770
The report provides revenue of the global critical limb ischemia treatment market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global critical limb ischemia treatment market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the critical limb ischemia treatment market.
The report delves into the competitive landscape of the global critical limb ischemia treatment market. Key players operating in the global critical limb ischemia treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global critical limb ischemia treatment market profiled in this report.
Table of Contents
1. Preface
- 1.1. Report Scope and Market Segmentation
- 1.2. Research Highlights
2. Assumptions and Research Methodology
- 2.1. Assumptions and Acronyms Used
- 2.2. Research Methodology
3. Executive Summary
4. Market Overview
- 4.1. Product Overview
- 4.2. Market Dynamics
- 4.2.1. Drivers and Restraints Snapshot Analysis
- 4.2.2. Drivers
- 4.2.3. Restraints
- 4.2.4. Opportunity
- 4.3. Global Critical Limb Ischemia Treatment Market Revenue Projection (US$ Mn), 2017-2027
- 4.4. Global Critical Limb Ischemia Treatment Market Outlook
5. Market Outlook
- 5.1. Pipeline Analysis
- 5.2. Key Industry Events
- 5.3. Regulatory Scenario for Device
- 5.4. Prevalence of Critical Limb Ischemia Globally/Region
- 5.5. Major Research Institutes Involved
- 5.6. Technological Advancement
6. Global Critical Limb Ischemia Treatment Market Analysis, by Treatment
- 6.1. Key Findings
- 6.2. Introduction
- 6.3. Global Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
- 6.4. Global Critical Limb Ischemia Treatment Market Forecast, by Treatment
- 6.4.1. Devices
- 6.4.2. Medication
- 6.5. Global Critical Limb Ischemia Treatment Market Analysis, by Treatment
7. Global Critical Limb Ischemia Treatment Market Analysis, by Region
- 7.1. Global Critical Limb Ischemia Treatment Market Scenario, by Country
- 7.2. Global Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Region
- 7.3. Global Critical Limb Ischemia Treatment Market Forecast, by Region
- 7.3.1. North America
- 7.3.2. Europe
- 7.3.3. Asia Pacific
- 7.3.4. Latin America
- 7.3.5. Middle East & Africa
8. North America Critical Limb Ischemia Treatment Market Analysis
- 8.1. Key Findings
- 8.2. North America Critical Limb Ischemia Treatment Market Overview
- 8.3. North America Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Country
- 8.4. North America Critical Limb Ischemia Treatment Market Forecast, by Country
- 8.4.1. U.S.
- 8.4.2. Canada
- 8.5. North America Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
- 8.6. North America Critical Limb Ischemia Treatment Market Forecast, by Treatment
- 8.6.1. Devices
- 8.6.2. Medication
9. Europe Critical Limb Ischemia Treatment Market Analysis
- 9.1. Key Findings
- 9.2. Europe Critical Limb Ischemia Treatment Market Overview
- 9.3. Europe Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
- 9.4. Europe Critical Limb Ischemia Treatment Market Forecast, by Country/Sub-region
- 9.4.1. Germany
- 9.4.2. France
- 9.4.3. U.K.
- 9.4.4. Italy
- 9.4.5. Spain
- 9.4.6. Rest of Europe
- 9.5. Europe Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
- 9.6. Europe Critical Limb Ischemia Treatment Market Forecast, by Treatment
- 9.6.1. Devices
- 9.6.2. Medication
10. Asia Pacific Critical Limb Ischemia Treatment Market Analysis
- 10.1. Key Findings
- 10.2. Asia Pacific Critical Limb Ischemia Treatment Market Overview
- 10.3. Asia Pacific Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
- 10.4. Asia Pacific Critical Limb Ischemia Treatment Market Forecast, by Country/Sub-region
- 10.4.1. Japan
- 10.4.2. China
- 10.4.3. India
- 10.4.4. Australia & New Zealand
- 10.4.5. Rest of Asia Pacific
- 10.5. Asia Pacific Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
- 10.6. Asia Pacific Critical Limb Ischemia Treatment Market Forecast, by Treatment
- 10.6.1. Devices
- 10.6.2. Medication
11. Latin America Critical Limb Ischemia Treatment Market Analysis
- 11.1. Key Findings
- 11.2. Latin America Critical Limb Ischemia Treatment Market Overview
- 11.3. Latin America Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
- 11.4. Latin America Critical Limb Ischemia Treatment Market Forecast, by Country/Sub-region
- 11.4.1. Brazil
- 11.4.2. Mexico
- 11.4.3. Rest of Latin America
- 11.5. Latin America Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
- 11.6. Latin America Critical Limb Ischemia Treatment Market Forecast, by Treatment
- 11.6.1. Devices
- 11.6.2. Medication
12. Middle East & Africa Critical Limb Ischemia Treatment Market Analysis
- 12.1. Key Findings
- 12.2. Middle East & Africa Critical Limb Ischemia Treatment Market Overview
- 12.3. Middle East & Africa Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
- 12.4. Middle East & Africa Critical Limb Ischemia Treatment Market Forecast, by Country/Sub-region
- 12.4.1. GCC Countries
- 12.4.2. South Africa
- 12.4.3. Rest of Middle East & Africa
- 12.5. Middle East & Africa Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
- 12.6. Middle East & Africa Critical Limb Ischemia Treatment Market Forecast, by Treatment
- 12.6.1. Devices
- 12.6.2. Medication
13. Competition Landscape
- 13.1. Competition Matrix
- 13.2. Company Profiles
- 13.2.1. Medtronic plc
- 13.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
- 13.2.1.2. Product Portfolio
- 13.2.1.3. SWOT Analysis
- 13.2.1.4. Strategic Overview
- 13.2.2. Boston Scientific Corporation
- 13.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
- 13.2.2.2. Product Portfolio
- 13.2.2.3. SWOT Analysis
- 13.2.2.4. Strategic Overview
- 13.2.3. Cesca Therapeutics, Inc.
- 13.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
- 13.2.3.2. Product Portfolio
- 13.2.3.3. SWOT Analysis
- 13.2.3.4. Strategic Overview
- 13.2.4. Abbott Laboratories
- 13.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
- 13.2.4.2. Product Portfolio
- 13.2.4.3. SWOT Analysis
- 13.2.4.4. Strategic Overview
- 13.2.5. Pluristem Therapeutics, Inc.
- 13.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
- 13.2.5.2. Product Portfolio
- 13.2.5.3. SWOT Analysis
- 13.2.5.4. Strategic Overview
- 13.2.6. Rexgenero Ltd.
- 13.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
- 13.2.6.2. Product Portfolio
- 13.2.6.3. SWOT Analysis
- 13.2.6.4. Strategic Overview
- 13.2.7. LimFlow SA
- 13.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
- 13.2.7.2. Product Portfolio
- 13.2.7.3. SWOT Analysis
- 13.2.7.4. Strategic Overview
- 13.2.8. Micro Medical Solutions
- 13.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
- 13.2.8.2. Product Portfolio
- 13.2.8.3. SWOT Analysis
- 13.2.8.4. Strategic Overview
- 13.2.9. Cardiovascular Systems, Inc.
- 13.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
- 13.2.9.2. Product Portfolio
- 13.2.9.3. SWOT Analysis
- 13.2.9.4. Strategic Overview
- 13.2.1. Medtronic plc
